Agilent Technologies (Santa Clara, California) plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets that will retain the Agilent name, and another that will encompass Agilent?s current portfolio of electronic measurement products.
Agilent Technologies (Santa Clara, California) plans to separate into two publicly traded companies: one in life sciences, diagnostics, and applied markets that will retain the Agilent name, and another that will encompass Agilent’s current portfolio of electronic measurement products.
The new electronic measurement company will be an electronic measurement company in major markets including communications, aerospace and defense, and industrial, computers, and semiconductors.
Agilent says it believes that the separation will result in material benefits to the standalone companies, including greater management focus on the distinct businesses of life sciences, diagnostics, and applied markets, and electronic measurement; ability for the life sciences, diagnostics, and applied markets company to devote resources to the higher-growth life sciences, diagnostics, and applied markets business, while reducing exposure to the more cyclical electronic measurement industry; ability for the electronic measurement company to devote resources to its own growth that were previously used to capitalize life sciences, diagnostics, and applied markets; and two independent and unique investment profiles. Additionally, both companies will be well capitalized, having strong balance sheets and investment-grade profiles with target debt-to-EBITDA ratios below 2.0x.
Free Poster: NDSRI Risk Assessment and Trace-Level Analysis of N-Nitrosamines
April 25th 2025With increasing concern over genotoxic nitrosamine contaminants, regulatory bodies like the FDA and EMA have introduced strict guidelines following several high-profile drug recalls. This poster showcases a case study where LGC and Waters developed a UPLC/MS/MS method for quantifying trace levels of N-nitroso-sertraline in sertraline using Waters mass spectrometry and LGC reference standards.
New Guide: Characterising Impurity Standards – What Defines “Good Enough?”
April 25th 2025Impurity reference standards (IRSs) are essential for accurately identifying and quantifying impurities in pharmaceutical development and manufacturing. Yet, with limited regulatory guidance on how much characterisation is truly required for different applications, selecting the right standard can be challenging. To help, LGC has developed a new interactive multimedia guide, packed with expert insights to support your decision-making and give you greater confidence when choosing the right IRS for your specific needs.
Using the Carcinogenic Potency Categorisation Approach (CPCA) to Classify N-nitrosamine Impurities
April 25th 2025Learn how to manage nitrosamine impurities in pharmaceuticals with our free infographic. Discover how the CPCA approach establishes acceptable intake limits and guides the selection of NDSRI reference samples. Stay compliant and ensure safety with our ISO-accredited standards.